Breast cancer: The second leading cause of cancer death in women

In the United States, breast cancer is the second leading cause of cancer death in women and only 1 in 4 diagnosed with metastases will reach 5-year survival.1,2

Indoximod is being studied in metastatic breast cancer3

NewLink Genetics’ indoximod is a small-molecule indoleamine 2,3-dioxygenase (IDO) pathway inhibitor that has the potential to disrupt mechanisms by which tumors evade the immune system.4,5
 

Learn about the IDO pathway and IDO pathway inhibitors

 
metastatic-n154
Learn more about the indoximod study in metastatic breast cancer

 

References

1. Centers for Disease Control and Prevention. Cancer among women. http://www.cdc.gov/cancer/dcpc/data/women.htm. Updated August 20, 2015. Accessed October 3, 2015. 2. National Cancer Institute. SEER stat fact sheets: breast cancer. http://seer.cancer.gov/statfacts/html/breast.html. Accessed October 4, 2015. 3. National Institutes of Health. Study of chemotherapy in combination with IDO inhibitor in metastatic breast cancer. http://clinicaltrials.gov/ct2/show/record/NCT01792050 . Accessed October 4, 2015. 4. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013;34(3):137-143. 5. Baban B, Chandler PR, Sharma MD, et al. IDO activates regulatory T cells and blocks their conversion into Th17-like helper T cells. J Immunol. 2009;183(4):2475-2483.